Torrent Pharmaceuticals revenue and financials
₹4,710.00Change from previous close: −1.42%Absolute change: −₹68.00
In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹139.8B (+21.39% year over year). Net income was ₹21.63B, a net margin of 15.5%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.39%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +13.19%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 15.5%
- FY to Mar 2025: 16.6%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Operating cash flow | 30,227 | 25,851 | 32,661 | 23,681 | 18,030 |
| Depreciation and amortization | 11,042 | 7,740 | 7,748 | 6,830 | 6,427 |
| Capital expenditure | -6,774 | -6,119 | -4,328 | -5,739 | -2,026 |
| Investing cash flow | -127,124 | -5,401 | -1,679 | -24,153 | -1,966 |
| Financing cash flow | 101,506 | -22,980 | -27,796 | 774 | -17,811 |
| Dividends paid | -12,889 | -10,830 | -10,153 | -5,132 | -6,769 |
| Debt issued | 125,941 | 0.0 | 0.0 | 22,370 | 2,186 |
| Debt repaid | -7,271 | -9,527 | -13,933 | -9,936 | -10,651 |
| Effect of exchange rates | 828 | -87.3 | 80.7 | 211 | 5.3 |
| Net change in cash | 5,437 | -2,617 | 3,266 | 1,101 | -1,742 |
| Free cash flow | 23,453 | 19,732 | 28,333 | 17,942 | 16,004 |
| Levered free cash flow | 26,013 | 12,787 | 22,213 | 14,783 | 10,209 |